1.Bene MC. Immunophenotyping of acute leukaemias. Immunol Lett. 2005. 98:9–21.
2.Casasnovas RO., Slimane FK., Garand R., Faure GC., Campos L., Deneys V, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia. 2003. 17:515–27.
Article
3.Bene MC., Bernier M., Castoldi G., Faure GC., Knapp W., Ludwig WD, et al. Impact of immunophenotyping on management of acute leukemias. Haematologica. 1999. 84:1024–34.
4.Kaleem Z., Crawford E., Pathan MH., Jasper L., Covinsky MA., Johnson LR, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med. 2003. 127:42–8.
5.Jennings CD., Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997. 90:2863–92.
Article
6.Paietta E., Andersen J., Gallagher R., Bennett J., Yunis J., Cassileth P, et al. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 1994. 8:1108–12.
7.Oelschlagel U., Nowak R., Mohr B., Thiede C., Ehninger G., Schaub A, et al. Specificity of immunophenotyping in acute promyelocytic leukemia. Cytometry. 2000. 42:396–7.
8.Exner M., Thalhammer R., Kapiotis S., Mitterbauer G., Knobl P., Haas OA, et al. The “typical” immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant? Cytometry. 2000. 42:106–9.
Article
9.Baer MR., Stewart CC., Dodge RK., Leget G., Sule N., Mrozek K, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001. 97:3574–80.
Article
10.Wetzler M., McElwain BK., Stewart CC., Blumenson L., Mortazavi A., Ford LA, et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 2003. 17:707–15.
Article
11.Orfao A., Chillon MC., Bortoluci AM., Lopez-Berges MC., Garcia-Sanz R., Gonzalez M, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica. 1999. 84:405–12.
12.Fenu S., Carmini D., Mancini F., Guglielmi C., Alimena G., Riccioni R, et al. Acute myeloid leukemias M2 potentially misdiagnosed as M3 variant French-American-Britain (FAB) subtype: a transitional form? Leuk Lymphoma. 1995. 18(S1):49–55.
Article
13.Lazarchick J., Hopkins M. HLA-Dr negative acute non-lymphocytic leukemia. Ann Clin Lab Sci. 1998. 28:150–2.
14.Jaffe ES HN., Stein H, et al. WHO classification of tumours: Tumours of Hematopoietic and Lymphoid tissue. Lyon: IARC Press;2001.
15.Bene MC., Castoldi G., Knapp W., Ludwig WD., Matutes E., Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995. 9:1783–6.
16.Guglielmi C., Martelli MP., Diverio D., Fenu S., Vegna ML., Cantu-Rajnoldi A, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998. 102:1035–41.
Article
17.Khoury H., Dalal BI., Nantel SH., Horsman DE., Lavoie JC., Shepherd JD, et al. Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol. 2004. 17:1211–6.
Article
18.Syampurnawati M., Tatsumi E., Furuta K., Takenokuchi M., Nakamachi Y., Kawano S, et al. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. Leuk Res. 2007. 31:921–9.
19.Kussick SJ., Stirewalt DL., Yi HS., Sheets KM., Pogosova-Agadjanyan E., Braswell S, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia. 2004. 18:1591–8.